Jose Igoa, MD
Psychiatry · McAllen, TXNPI 1780615732
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $699,605 of the $820,852 with a category attached, or 85.2%. 34 manufacturers reported payments, led by AbbVie at 45.8% of the total. Among psychiatry clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,920 payments — averaging $427.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$376K
- Alkermes, Inc.$101K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$94K
- Neurocrine Biosciences, Inc.$59K
- Supernus Pharmaceuticals, Inc.$58K
- Otsuka America Pharmaceutical, Inc.$32K
- plus $101K from 28 others
What the payments were for
- Consulting fees$43,4255%
- Speaking & faculty fees$699,60585%
- Travel & lodging$40,0405%
- Food & beverage$37,5305%
- Education$2520%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$368,675
- ARISTADA$215,266
- LYBALVI$190,501
- CAPLYTA$91,849
- INGREZZA$57,765
- QELBREE$52,099
- ARISTADA INITIO$41,932
- ABILIFY MAINTENA$28,820
- JORNAY PM$21,363
- Auvelity$20,132
- AUSTEDO$15,302
- Fanapt$13,974
- COBENFY$8,494
- Jornay PM 20mg capsules (Bottle of 100)$5,985
- UZEDY$1,462
- QUVIVIQ$1,190
- REXULTI$877
- LATUDA$700
- Austedo XR$228
- ABILIFY ASIMTUFII$128
How this compares
$820,852 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 89 | $126,548 |
| Austedo XrDeutetrabenazine | 19 | $125,282 |
| RexultiBrexpiprazole | 66 | $92,694 |
| CaplytaLumateperone Tosylate | 38 | $62,008 |
| AristadaAripiprazole Lauroxil | 17 | $55,636 |
| Invega SustennaPaliperidone Palmitate | 15 | $52,347 |
| TrintellixVortioxetine Hydrobromide | 77 | $42,335 |
| Lurasidone Hcl | 130 | $32,512 |
| VyvanseLisdexamfetamine Dimesylate | 79 | $31,472 |
| LybalviOlanzapine/Samidorphan Malate | 17 | $26,706 |
| Lisdexamfetamine Dimesylate | 126 | $23,416 |
| BelsomraSuvorexant | 46 | $22,258 |
| Clozapine | 207 | $21,988 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 200 | $14,336 |
| ClozarilClozapine | 11 | $12,223 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Savella | $376,053 | $133,789103 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $19,799 | $125,28219 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $31,930 | $92,69466 claims |
| Alkermes, Inc.Aristada, Lybalvi | $100,509 | $82,34234 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $657 | $73,808156 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $94,024 | $62,00838 claims |
| Johnson & JohnsonInvega Sustenna | $511 | $52,34715 claims |
| MerckBelsomra | $85 | $22,25846 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $1,288 | $5,99112 claims |
| Almatica Pharma LLCSertraline Hcl | $26 | $2,265279 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in McAllen
- Rakesh JainLake Jackson$7.2M
- Arvinder Pal WaliaAustin$2.5M
- Suresh SureddiPlano$2.2M
- Martin GuerreroEl Paso$2M
- Marty BennettAddison$1.8M
- Matthew BramsHouston$1.5M
- Vikram MehraKaty$1.2M
- Joel HolinerDallas$948K
- Frank ChenHouston$941K
- Alice MaoHouston$850K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.